Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04026997Phase 2Terminated

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Role: lead

NCT06899217Phase 2Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.

Role: lead

NCT05832151Phase 2Completed

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

Role: lead

NCT04208698Phase 2Terminated

A Scintigraphy Study in Adults With Diabetic Gastroparesis

Role: lead

All 4 trials loaded